Revenue and Profit - The company's revenue for Q1 2024 was ¥104,561,855.22, a decrease of 10.78% compared to ¥117,201,090.18 in the same period last year[5] - Net profit attributable to shareholders increased by 9.37% to ¥13,357,813.44 from ¥12,213,813.89 year-on-year[5] - The company achieved operating revenue of CNY 104,561,855.22, a year-on-year decrease of 10.78%[12] - Net profit attributable to the listed company was CNY 13,357,813.44, an increase of 9.37% year-on-year[12] - Net profit for Q1 2024 reached CNY 13,357,813.44, an increase of 9.4% from CNY 12,213,813.89 in Q1 2023[19] Earnings Per Share - Basic and diluted earnings per share rose by 9.33% to ¥0.1113 from ¥0.1018 in the same period last year[5] - Basic and diluted earnings per share for Q1 2024 were both CNY 0.1113, compared to CNY 0.1018 in Q1 2023[20] Cash Flow - The net cash flow from operating activities significantly dropped by 84.14%, amounting to ¥4,680,974.46 compared to ¥29,506,108.77 in the previous year[5] - The net cash flow from operating activities for the current period is ¥4,680,974.46, a decrease of 84.2% compared to ¥29,506,108.77 in the previous period[23] - Cash inflow from operating activities totaled ¥110,901,566.65, down 21.5% from ¥141,311,878.19 in the previous period[23] - Cash outflow from operating activities was ¥106,220,592.19, a decrease of 5.0% compared to ¥111,805,769.42 in the previous period[23] - The net cash flow from investing activities is -¥29,319,647.03, an improvement from -¥53,605,687.16 in the previous period[23] - Cash inflow from financing activities was ¥30,000,000.00, down 38.8% from ¥49,000,000.00 in the previous period[23] - The net cash flow from financing activities is -¥2,302,894.43, a significant decline compared to ¥21,493,951.38 in the previous period[23] - The ending balance of cash and cash equivalents is ¥19,874,244.44, a decrease from ¥92,465,697.80 in the previous period[23] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,411,909,020.32, reflecting a slight increase of 0.22% from ¥1,408,864,380.40 at the end of the previous year[5] - Total liabilities decreased to CNY 411,047,921.63 from CNY 421,368,242.18 year-over-year[16] - Non-current assets totaled CNY 1,058,467,056.30, an increase from CNY 1,031,568,551.09 in Q1 2023[16] Research and Development - Research and development expenses surged by 80.20% to ¥5,429,812.44, indicating increased investment in innovation[8] - Research and development expenses increased to CNY 5,429,812.44, up 80.5% from CNY 3,013,143.82 in the previous year[19] Sales Performance - Sales of the main product, rivaroxaban tablets, increased by 56.32% in volume and 53.88% in sales amount compared to the same period last year[14] - Sales of the injection of landiolol hydrochloride reached CNY 6,075,000, with a volume increase of 28.46% year-on-year[14] - The company reported a significant increase in sales of cefmetazole injection, with a volume increase of 6680.00% year-on-year[14] Shareholder Information - The largest shareholder, Mr. Cao Yuping, holds 42.08% of the shares, while the second-largest shareholder, Ms. Jiang Xiaoqin, holds 9.98%[10] Other Financial Metrics - The weighted average return on equity slightly improved to 1.34% from 1.28% year-on-year[5] - The company recorded a total of ¥39,253.47 in government subsidies related to its normal business operations[6] - Total operating costs for Q1 2024 were CNY 85,582,384.45, down 16.2% from CNY 102,187,516.82 in the same period last year[18] - Inventory as of the end of Q1 2024 was CNY 87,529,909.40, an increase from CNY 81,455,425.23 at the end of Q1 2023[16] - Accounts receivable stood at CNY 200,965,069.16, slightly down from CNY 206,779,467.11 at the beginning of the period[14] Employee and Tax Expenses - The company paid ¥24,165,067.57 in employee compensation, an increase of 5.7% from ¥21,925,357.04 in the previous period[23] - The company incurred tax payments of ¥17,967,780.68, up 21.4% from ¥14,841,281.98 in the previous period[23] - The company reported a cash outflow of ¥41,888,347.37 related to other operating activities, a decrease of 29.7% from ¥59,527,108.18 in the previous period[23] Strategic Focus - The company is focusing on refining sales management and adjusting product structure to improve performance[12] - Sales expenses decreased by 35.36% to ¥38,595,773.27, attributed to optimized sales strategies and improved sales personnel efficiency[8]

Financial Performance - The company's operating revenue for 2023 was ¥517,832,192, a decrease of 1.64% compared to ¥526,465,340 in 2022[19] - The net profit attributable to shareholders for 2023 was ¥36,315,554, an increase of 11.92% from ¥32,448,867 in 2022[19] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥36,965,334, reflecting a 17.51% increase from ¥31,458,351 in 2022[19] - The net cash flow from operating activities improved significantly to ¥23,932,692, a 511.26% increase from a negative cash flow of ¥5,819,338 in 2022[19] - The total assets at the end of 2023 were ¥1,408,864,380.40, an increase of 8.88% from ¥1,293,945,410.29 at the end of 2022[19] - The net assets attributable to shareholders increased to ¥987,496,138.22, up 3.89% from ¥950,566,396.43 at the end of 2022[19] - The basic earnings per share for 2023 were ¥0.3026, an increase of 11.91% compared to ¥0.2704 in 2022[19] - The diluted earnings per share also stood at ¥0.3026, reflecting the same growth of 11.91% from the previous year[19] - The weighted average return on equity for 2023 was 3.75%, an increase from 3.42% in 2022[19] Market and Product Development - The company plans to continue focusing on new product development and market expansion strategies to enhance future growth prospects[3] - The company has launched multiple high-quality products with significant market shares, including an injectable form of Torasemide, which achieved a market share of approximately 80% in its category[35] - The injectable form of Labetalol is a unique first-to-market product with two core patents, recommended in multiple clinical guidelines, and has been continuously included in the National Medical Insurance Directory[38] - Rivaroxaban tablets, the first oral direct Factor Xa inhibitor, have been included in several authoritative treatment guidelines and won bids in the national centralized procurement, enhancing the product's market competitiveness[39] - Tigecycline injection, known as a "super antibiotic," is included in the National Medical Insurance Directory and has been selected in the national centralized procurement, which is expected to increase its market share[40] - The injectable form of Torasemide is a new generation diuretic with strong and rapid effects, but its sales have been impacted by low-priced competitors in certain markets[41] - The company has established a comprehensive procurement, production, and sales system to ensure product quality and stable supply[42] - The company employs a sales model that emphasizes refined management and tracking of sales processes in hospitals to enhance market penetration[43] Research and Development - The company has established a comprehensive R&D system with over 60 dedicated personnel, focusing on drug development and innovation[45] - The company is actively involved in national and provincial-level technology projects, enhancing its R&D capabilities through collaboration with NMS Group, a leading European oncology drug research institution[46] - The company has submitted 3 invention patent applications and received authorization for 1 invention patent during the reporting period[57] - A total of 4 products (6 specifications) were approved for market by the National Medical Products Administration, including 4 generic products and 2 consistency evaluation products[57] - The company has 17 key research projects underway, with plans to submit several generic drug registration applications in 2024[60][61] Financial Management and Cost Control - The company achieved a production cost control and improved inventory efficiency, contributing to overall cost reduction[62] - The company reported a decrease in raw material costs by 29.79% to ¥43,526,694.72, contributing to improved margins[75] - The total sales expenses decreased by 10.09% to ¥241,595,638.54, reflecting cost control measures[80] - The company experienced a significant increase in depreciation expenses, which fell by 37.42% to ¥9,968,322.52[75] - The company’s investment activities generated a net cash outflow of ¥137,266,120.14, a decrease of 571.42% year-on-year[84] Corporate Governance - The company has established a comprehensive governance structure to ensure effective decision-making and protect shareholder rights[112] - The company maintains complete independence from its controlling shareholders in terms of assets, personnel, finance, organization, and business operations[115] - The board of directors includes a strategic committee, audit committee, nomination committee, and compensation and assessment committee to enhance governance[113] - The company has established a performance evaluation and incentive mechanism for directors, supervisors, and senior management, linking their compensation to company performance and individual achievements[114] - The company has a complete research, production, and sales system, ensuring independent business operations[115] Environmental Responsibility - The company adheres to environmental regulations and has established a comprehensive environmental management system, meeting various national and local standards for wastewater and air emissions[164] - The company obtained an environmental protection administrative permit for wastewater discharge, valid from September 1, 2022, to August 31, 2027[164] - The company has implemented a comprehensive waste gas treatment system to manage emissions from various production processes, ensuring compliance with local environmental standards[169] - The company has established protocols for the management of hazardous waste, ensuring safe handling and disposal in accordance with environmental regulations[170] - The company invested 3.5683 million yuan in environmental governance and protection during the reporting period[174] Community Engagement - The company donated a total of 500,000 RMB worth of materials to the Hai Chen Hope Primary School during the Children's Day event[180] - Cumulative donations reached 690,000 RMB through participation in charity events in Jiangsu Province over the past three years[180] - The company provided over 490,000 RMB in various forms of assistance, benefiting 442 individuals during the reporting period[180]

南京海辰药业股份有限公司 2023 年度财务决算报告 一、2023 年度公司财务报告的审计情况 南京海辰药业股份有限公司（以下简称："公司"）编制的 2023 年财务报表已 经天衡会计师事务所（特殊普通合伙）审计，并出具了标准无保留意见的审计报告 （天衡审字(2024)00493 号），现将公司2023 年度的财务决算情况报告如下： 二、主要财务数据和指标 | 单位：万元 | | --- | | 项目 | 2023 年 | 2022 年 | 本年比上年 | | --- | --- | --- | --- | | | | | 增减 | | 营业收入 | 51,783.22 | 52,646.53 | -1.64% | | 归属于上市公司股东的净利润 | 3,631.56 | 3,244.89 | 11.92% | | 归属于上市公司股东的扣除非 经常性损益的净利润 | 3,696.53 | 3,145.84 | 17.51% | | 经营活动产生的现金流量净额 | 2,393.27 | -581.93 | 511.26% | | 基本每股收益（元/股） | 0.3026 | 0.2704 | 11.91% | ...

2023 年正值公司成立二十周年，面对行业竞争加剧、市场信心不足等诸多不利因 素影响，全体员工在董事会和管理层的带领下，扎实推进降本增效，持续投入药品研 发，不断丰富业务板块，始终坚持高质量发展。报告期内公司实现营业收入 5.18 亿 元，同比下降 1.64%；归属于上市公司股东的净利润 3,631.56 万元，同比上升 11.92%，归属于上市公司股东的扣除非经常性损益的净利润 3,696.53 万元，同比上升 17.51%。2023 年，公司各项重点工作完成情况如下： （1）积极落实营销部署，深化重点品种终端覆盖。 2023 年，公司营销系统围绕年度推广目标，致力于提升重点品种注射用盐酸兰地 洛尔、利伐沙班片、注射用替加环素等的终端覆盖。报告期内，注射用盐酸兰地洛尔 于 2023 年底以简易续约方式再次被纳入国家医保目录，入选《国家心力衰竭指南》 （2023 版），被列为急性心衰发作患者的心室率控制推荐用药；公司持续深入推进该 品种医院开发工作，通过专业化的学术推广，已成功开发约 650 家三级医院、约 270 家二级医院，较上年新增约 170 家医院，实现销量翻倍。利伐沙班片 15mg 和 20mg 作 ...

南京海辰药业股份有限公司 在执行审计工作的过程中，天衡就会计师事务所和相关审计人员的独立性、 天衡会计师事务所（特殊普通合伙）（以下简称"天衡"）成立于 2013 年， 注册地址在江苏省南京市建邺区江东中路 106 号 1907 室，首席合伙人为郭澳。 截至 2023 年 12 月 31 日合伙人 85 人，注册会计师 419 人，签署过证券业务审计 报告的注册会计师 222 人。2023 年度业务总收入 61,472.84 万元、审计业务收 入 55,444.33 万元、证券业务收入 16,062.01 万元。 （二）聘任会计师事务所履行的程序 第四届董事会第七次会议及 2022 年年度股东大会审议通过了《关于续聘 2023 年度审计机构的议案》，同意续聘天衡会计师事务所（特殊普通合伙）为公 司 2023 年度财务审计机构，聘期一年。公司独立董事就该议案发表了事前认可 意见及同意的独立意见。 二、2023 年年审会计师事务所履职情况 按照《审计业务约定书》，遵循《中国注册会计师审计准则》和其他执业规 范，以及公司 2023 年年报工作安排，天衡对公司 2023 年度财务报告进行了审 计，同时对公司非经营性资 ...

南京海辰药业股份有限公司 2023年度非经营性资金占用及其他关联资金往来情况汇总表 单位：人民币万元 公司法定代表人： 主管会计机构负责人： 会计机构负责人： 附件： | 非经营性资金占用 | 资金占用方名称 | 占用方与上市公司的 关联关系 | 上市公司核算的 会计科目 | 2023年期初占用 资金余额 | 2023年度年度 占用累计发生金 | 2023年度占用 资金的利息 | 2023年度偿还 累计发生金额 | 2023年期末占 用资金余额 | 占用形成原因 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 额（不含利息） | （如有） | | | | | | 控股股东、实际控制人及其附属 | | | | | | | | | | | | 企业 | | | | | | | | | | | | 小计 | | | | | | | | | | | | 前控股股东、实际控制人及其附 | | | | | | | | | | | | 属企业 | | | | | | | | | | | | 小 ...

南京海辰药业股份有限公司 选聘会计师事务所专项制度 （2024年4月） 第一章 总 则 第五条 公司选聘的会计师事务所应当具备以下条件： （一）具有《证券法》规定的任职要求； （二）具有固定的工作场所、健全的组织机构和完善的内部管理和控制制度； （三）熟悉国家有关财务会计方面的法律、法规、规章和政策； （四）具有完成审计任务和确保审计质量的注册会计师； 第一条 为规范南京海辰药业股份有限公司（以下简称"公司"）选聘（含 续聘、改聘，下同）执行年报审计业务的会计师事务所的有关行为，根据中国 证券监督管理委员会（以下简称"中国证监会"）的相关规定，特制定本制 度。 第二条 公司选聘执行年报审计业务的会计师事务所，遵照本制度履行选聘 程序，披露相关信息。 第三条 公司选聘会计师事务所应当经董事会审计委员会审核，经董事会、 股东大会审议，未经公司董事会、股东大会审议批准前，公司不得聘请会计师 事务所开展年度审计业务。 第四条 公司大股东、实际控制人不得在公司董事会、股东大会审议前，向 公司指定会计师事务所，不得干预审计委员会独立履行审核职责。 第二章 会计师事务所执业质量要求 （五）认真执行国家和省有关财务审计的法律 ...

南京海辰药业股份有限公司 2023 年度内部控制评价报告 南京海辰药业股份有限公司全体股东： 根据《企业内部控制规范》及其配套指引和其他内部控制监管要求（以下简 称企业内部控制规范体系），结合本公司（以下简称公司）内部控制制度和评价 办法，在内部控制日常监督和专项监督的基础上，我们对公司 2023 年 12 月 31 日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一、重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其 有效性，并如实披露内部控制评价报告是公司董事会的责任。监事会对董事会建 立和实施内部控制进行监督。管理层负责组织领导企业内部控制的日常运行。公 司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存在任何虚假 记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个 别及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合理合规、资产安全、财务报 告及相关信息真实完整，提高经营效率和效果，促进实现发展战略。由于内部控 制存在的固有局限性，故仅能为实现上述目标提供合理保证。此外，由于情况的 变化可能导致内部控制变得不恰当，或对控制政策 ...

南京海辰药业股份有限公司 根据《上市公司独立董事管理办法》《上市公司自律监管指引第 2 号--创业 板上市公司规范运作》等要求，独立董事应当每年对独立性进行自查，并将自查 情况提交董事会。董事会应当每年对在任独立董事独立性情况进行评估并出具专 项意见。基于此，南京海辰药业股份有限公司（以下简称"公司"）董事会，就 公司在任独立董事李翔、赵鸣、毛凌霄的独立情况进行评估并出具如下专项意见： 经公司独立董事自查及董事会核查独立董事在公司的履职情况，董事会认为 公司全体独立董事均具备胜任独立董事岗位的资格。独立董事及其配偶、父母、 子女、主要社会关系未在公司或公司附属企业任职，未在公司主要股东及其附属 企业任职，未与公司存在重大的持股关系，与公司以及主要股东之间不存在重大 业务往来关系或提供财务、法律、咨询、保荐等服务关系。综上，独立董事不存 在任何妨碍其进行独立客观判断的关系，不存在影响独立董事独立性的情况，符 合《上市公司独立董事管理办法》等法律法规及《公司章程》中关于独立董事的 任职资格及独立性的要求。 南京海辰药业股份有限公司董事会 董事会关于独立董事独立性情况的专项意见 2024 年 4 月 24 日 ...

关于南京海辰药业股份有限公司 2023 年度非经营性资金占用及其他关联 资金往来情况的专项说明 天衡专字(2024)00318 号 关于南京海辰药业股份有限公司 2023 年度非经营性资金占用及其他关联 资金往来情况的专项说明 天衡专字(2024)00318 号 天衡会计师事务所（特殊普通合伙） 2024 年 4 月 24 日 附件: 南京海辰药业股份有限公司 2023年度非经营性资金占用及其他关联资金往来情况汇总表 单位:人民币万元 2023年度年度 2023年度占用 占用方与上市公司的 上市公司核算的 2023年期初占用 2023年度偿还 2023年期末占 非经营性资金占用 资金占用方名称 占用累计发生金 资金的利息 占用形成原因 占用性质 累计发生金额 关联关系 会计科目 资金余额 用资金余额 額(不含利息) (如有) 控股服东,实际控制人及其附属 企业 小计 前控股股东、实际控制人及其附 属企业 小 计 其他关联方及其財属企业 小 计 总计 2023年度往来累 | 2023年度往来 往来方与上市公司的 上市公司核算的 2023年期初往来 2023年度偿还累 2023年期末往来 其它关联资金往来 资金往 ...